Scopus BioPharma Inc. (SCPS) |
|
0.06075 -0.009 (-13.09%)
|
03-31 13:47 |
|
Open: |
0.06 |
Pre. Close: |
0.0699 |
|
High:
|
0.07 |
Low:
|
0.057 |
|
Volume:
|
14,313 |
Market Cap:
|
1(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:21:57 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.1 One year: 0.12 |
| Support: |
Support1: 0.05 Support2: 0.04 |
| Resistance: |
Resistance1: 0.08 Resistance2: 0.1 |
| Pivot: |
0.07  |
| Moving Average: |
MA(5): 0.06 MA(20): 0.07
MA(100): 0.13 MA(250): 0.29 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 24.1  %D(3): 18.2 |
| RSI: |
RSI(14): 41.2 |
| 52-week: |
High: 0.75 Low: 0.05 |
| Average Vol(K): |
3-Month: 24 (K) 10-Days: 15 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SCPS ] has closed above bottom band by 6.9%. Bollinger Bands are 66.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.07 - 0.07 |
0.07 - 0.07 |
|
Low:
|
0.06 - 0.06 |
0.06 - 0.06 |
|
Close:
|
0.06 - 0.06 |
0.06 - 0.06 |
|
Company Description |
|
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York. |
Headline News |
Fri, 16 Dec 2022
SCOPUS BIOPHARMA INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) - Marketscreener.com
Wed, 07 Dec 2022
Why iBio Shares Are Trading Lower By Around 48%; Here Are 23 ... - Benzinga
Thu, 10 Nov 2022
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer - Yahoo Finance
Tue, 18 Oct 2022
Scopus Biopharma Completes Recapitalization Designed To ... - GlobeNewswire
Wed, 21 Sep 2022
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Wed, 08 Sep 2021
Scopus BioPharma Inc. (NASDAQ: SCPS) Unveils Duet ... - BP Journal
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
21 (M) |
| Shares Float |
11 (M) |
|
% Held by Insiders
|
50.6 (%) |
|
% Held by Institutions
|
2.1 (%) |
|
Shares Short
|
24 (K) |
|
Shares Short P.Month
|
19 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-460.9 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.78 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-12 (M) |
|
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.11 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
